$0.26
(Market cap
$1,510 Mln
Revenue (TTM)
$2,297 Mln
P/E Ratio
--
P/B Ratio
1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.5 %
-
ROCE
-- %
-
Industry P/E
44.46
-
EV/EBITDA
22.4
-
Debt to Equity
0.8
-
Book Value
$--
-
EPS
$-19.4
-
Face value
--
-
Shares outstanding
57,669,494
10 Years Aggregate
CFO
$2,249.79 Mln
EBITDA
$4,241.89 Mln
Net Profit
$1,089.42 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Enovis Corp (ENOV)
| -5.8 | -11.2 | 8.6 | -19.1 | -23.5 | -21.5 | -7.1 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Enovis Corp (ENOV)
| -39.3 | -21.5 | 4.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Enovis Corp (ENOV)
|
25.1 | 1,509.8 | 2,296.6 | -1,101.7 | -44.1 | -74.3 | -- | 1.0 |
| 61.9 | 8,484.6 | 616.9 | -75.1 | 1.7 | -9.3 | -- | 10.1 | |
| 14.5 | 9,638.1 | 6,561.1 | -578.0 | -4.5 | -10.3 | -- | 1.7 | |
| 365.1 | 9,761.6 | 2,589.3 | 222.4 | -6.0 | 3 | 44.5 | 1.3 | |
| 57.5 | 9,074.5 | 3,499.6 | -71.2 | 0.5 | -3.2 | -- | 3.8 | |
| 180.0 | 10,905.5 | 612.8 | -188.1 | -30.6 | -28.1 | -- | 16.4 | |
| 100.5 | 6,525.3 | 1,556.3 | 275.3 | 24.6 | 22.9 | 24 | 5.0 | |
| 90.3 | 5,420.5 | 1,579.2 | 145.6 | 14.3 | 8.9 | 37.2 | 3.2 | |
| 321.8 | 12,752.7 | 1,504.9 | 160.6 | 13.6 | 10.9 | 79.4 | 8.4 | |
| 178.2 | 10,222.2 | 785.1 | 41.5 | 9.9 | 2 | 251.6 | 4.8 |
Shareholding Pattern
View DetailsAbout Enovis Corp (ENOV)
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The... Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware. Read more
-
CEO & Chairman
Mr. Matthew L. Trerotola
-
CEO & Chairman
Mr. Matthew L. Trerotola
-
Headquarters
Wilmington, DE
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Enovis Corp (ENOV)
What is the current share price of Enovis Corp (ENOV) Today?
The share price of Enovis Corp (ENOV) is $25.09 (NYSE) as of 28-Aug-2026 13:40 EDT. Enovis Corp (ENOV) has given a return of -23.51% in the last 3 years.
What is the current PB & PE ratio of Enovis Corp (ENOV)?
Since, TTM earnings of Enovis Corp (ENOV) is negative, P/E ratio is not available.
The P/B ratio of Enovis Corp (ENOV) is 1.03 times as on 21-Aug-2026, a 73 discount to its peers’ median range of 3.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-1.28 |
1.02 |
2024 |
-3.10 |
1.00 |
2023 |
-91.96 |
0.89 |
2022 |
-218.35 |
0.84 |
2021 |
70.19 |
1.09 |
What is the 52 Week High and Low of Enovis Corp (ENOV)?
The 52-week high and low of Enovis Corp (ENOV) are Rs 34.26 and Rs 19.14 as of 29-Aug-2026.
What is the market cap of Enovis Corp (ENOV)?
Enovis Corp (ENOV) has a market capitalisation of $ 1,510 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Enovis Corp (ENOV)?
Before investing in Enovis Corp (ENOV), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.